Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

BresaGen's lead anticancer compound E21R licensed to British Biotech

Jan. 2, 2001

Enzon seeks FDA approval to clinically evaluate PEG-paclitaxel

Jan. 2, 2001

Neovastat pivotal trial for third cancer indication approved in U.S. and Canada

Jan. 2, 2001

Gilead's NX-211 enters phase II for second cancer indication

Dec. 29, 2000

Sumitomo licenses class of DACH platinum compounds to Aronex

Dec. 29, 2000

Genta's anti-androgen compounds inhibit prostate cancer

Dec. 29, 2000

Combination tgDCC-E1A/radiation therapy enters phase II

Dec. 28, 2000

Pharmaccine collaboration between Oxxon Pharmaccines and Ludwig Institute

Dec. 28, 2000

Orphan grants Kirin Brewery marketing and distribution rights to Busulfex for Asia

Dec. 28, 2000

Bioenvision to codevelop clofarabine for leukemia; mode of action examined at UCSD

Dec. 28, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for July 21, 2026
To viral or not to viral: In vivo CAR T debates delivery tech
BioWorld Science
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
To viral or not to viral: In vivo CAR T debates delivery tech
BioWorld Asia
The field of cell and gene therapy is moving toward a new phase of scalability and clinical durability, with in vivo chimeric antigen receptor (CAR) T-cell...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...